-
公开(公告)号：US09566364B2
公开(公告)日：2017-02-14
申请号：US12636620
申请日：2009-12-11
Applicant: Michael Dockal , Friedrich Scheiflinger , Hans Christian Hedrich , Klaus Tschetschkowitsch , Andreas Goppelt
Inventor： Michael Dockal , Friedrich Scheiflinger , Hans Christian Hedrich , Klaus Tschetschkowitsch , Andreas Goppelt
CPC classification number: A61L24/106 , A61L24/043 , A61L2400/04
Abstract: The present invention provides a preparation comprising fibrinogen and a sulfated polysaccharide as a one component composition or as a kit of parts comprising fibrinogen and sulfated polysaccharide as separated components.The present invention further provides a fibrin clot like structure obtainable by a defined process, a hemostatic patch, a two-component syringe system and various uses of the described preparations, fibrin clot like structures and patches.
Abstract translation: 本发明进一步提供可通过限定的方法获得的纤维蛋白凝块样结构，止血贴剂，双组分注射器系统以及所述制剂，纤维蛋白凝块样结构和贴剂的各种用途。
-
公开(公告)号：US09272021B2
公开(公告)日：2016-03-01
申请号：US13493926
申请日：2012-06-11
Applicant: Friedrich Scheiflinger , Peter Turecek , Bruce Ewenstein , Wing Yen Wong , Tobias M. Suiter
Inventor： Friedrich Scheiflinger , Peter Turecek , Bruce Ewenstein , Wing Yen Wong , Tobias M. Suiter
CPC classification number: A61K38/36 , A61K38/37 , A61K2300/00
Abstract: The present invention provides methods of treating coagulation disease, including hemophilia and von Willebrand disease by administering recombinant von Willebrand Factor alone or in combination with Factor VIII.
Abstract translation: 本发明提供通过单独施用重组血管性血友病因子或与因子VIII组合来治疗凝血疾病的方法，包括血友病和血管性血友病。
-
公开(公告)号：US08632991B2
公开(公告)日：2014-01-21
申请号：US13006396
申请日：2011-01-13
Applicant: Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger
Inventor： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger
CPC classification number: G01N33/86 , A61K31/737 , A61K38/36 , A61K38/37 , Y10T436/106664 , Y10T436/107497 , Y10T436/178459 , Y10T436/18 , Y10T436/255 , A61K2300/00
Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.
Abstract translation: 本发明的方面包括用于增强受试者血液凝固的方法。 在根据某些实施方案的实践方法中，将一定量的非抗凝血硫酸多糖（NASP）施用于受试者以增强受试者的血液凝固。 还提供了制备具有凝血增强活性的NASP组合物的方法。 还描述了用于本发明的实践方法的组合物和试剂盒。
-
公开(公告)号：US08466108B2
公开(公告)日：2013-06-18
申请号：US12643818
申请日：2009-12-21
Applicant: Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger , Ulf Reimer , Ulrich Reineke , Thomas Polakowski , Eberhard Schneider
Inventor： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger , Ulf Reimer , Ulrich Reineke , Thomas Polakowski , Eberhard Schneider
IPC: A61K38/36 , A61K38/37 , A61K38/10 , A61K38/00 , A61K38/04 , A61K38/16 , C07K14/745 , C07K14/755
CPC classification number: C07K14/4703 , A61K38/00 , A61K47/551 , A61K47/557 , A61K47/60 , C07K7/08 , C07K14/001 , Y02A50/463
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
Abstract translation: 本发明提供了结合组织因子途径抑制剂（TFPI），包括TFPI抑制肽的肽及其组合物。 肽可以用于抑制TFPI，增强凝血因子缺陷受试者中的凝血酶形成，增加受试者中的血块形成和/或治疗受试者的血液凝固障碍。
-
5.发明授权Procedure for the generation of a high producer cell line for the expression of a recombinant anti-CD34 antibody 有权用于产生用于表达重组抗CD34抗体的高生产细胞系的方法公开(公告)号：US08399249B2
公开(公告)日：2013-03-19
申请号：US12389265
申请日：2009-02-19
Applicant: Randolf Kerschbaumer , Petra Boeck-Taferner , Friedrich Scheiflinger
Inventor： Randolf Kerschbaumer , Petra Boeck-Taferner , Friedrich Scheiflinger
CPC classification number: G01N33/6854 , C07K16/2896 , C07K2317/56
Abstract: The present invention relates to cell capture assay for the selection of a high producer cell line expressing anti-CD34 antibodies that recognize the CD34 membrane-protein in the cell membrane. The monoclonal antibody secreted by the hybridoma cell line 9C5/9069 binds to human CD34 and is used to isolate stem cells. The DNA sequences encoding for the antibody heavy and light chain have been identified, isolated from the hybridoma cells and cloned into appropriate expression vectors. After co-transfection of the heavy and light chain genes into HEK293T or in CHO cells either conditioned medium or purified antibody were assessed for binding to CD34 protein located in the cell membrane in different cell capture assays. The binding of the antibody to CD34-positive cells could be shown with these assays for several cell lines.
Abstract translation: 本发明涉及用于选择识别细胞膜中CD34膜蛋白的抗CD34抗体的高生产细胞系的细胞捕获测定。 由杂交瘤细胞系9C5 / 9069分泌的单克隆抗体与人CD34结合并用于分离干细胞。 已经鉴定了编码抗体重链和轻链的DNA序列，从杂交瘤细胞中分离并克隆到合适的表达载体中。 将重链和轻链基因共转染到HEK293T或CHO细胞中后，评估条件培养基或纯化抗体与不同细胞捕获试验中位于细胞膜中的CD34蛋白结合。 抗体与CD34阳性细胞的结合可以用几种细胞系的这些测定法显示出来。
-
Patent Agency Ranking
公开(公告)号：US20110118188A1
公开(公告)日：2011-05-19
申请号：US12388665
申请日：2009-02-19
Applicant: PETRUS JOHANNES LENTING , JAN AART VAN MOURIK , KOENRAAD MERTENS , HANS PANNEKOEK , PETER TURECEK , HANS-PETER SCHWARZ , FRIEDRICH SCHEIFLINGER
Inventor： PETRUS JOHANNES LENTING , JAN AART VAN MOURIK , KOENRAAD MERTENS , HANS PANNEKOEK , PETER TURECEK , HANS-PETER SCHWARZ , FRIEDRICH SCHEIFLINGER
IPC: A61K38/37 , C07K14/755 , A61P7/00
CPC classification number: C07K14/755 , A61K38/00 , A61K38/37 , C07K14/705 , A61K2300/00
Abstract: Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.
Abstract translation: 具有FVIII：C活性的因子VIII多肽，其含有因子VIII轻链序列的A3和/或C1和/或C2结构域的修饰，其特征在于与低密度脂蛋白受体蛋白的结合亲和力，以及生产方法 一样。
-
7.发明申请IMMUNOADSORPTION OF ANTI-VON WILLEBRAND FACTOR CLEAVING PROTEASE ANTIBODIES 有权免疫抵抗抗体抗体的抗体WILLEBRAND因子公开(公告)号：US20090264631A1
公开(公告)日：2009-10-22
申请号：US12388450
申请日：2009-02-18
Applicant: Friedrich Scheiflinger , Barbara Plaimauer , Gerhard Antoine
Inventor： Friedrich Scheiflinger , Barbara Plaimauer , Gerhard Antoine
CPC classification number: C12N9/6416 , A61K2039/505 , C07K14/755 , C07K16/40 , C12Q1/56 , G01N33/86
Abstract: This invention relates to adsorbents and methods for highly selective removal of anti-von Willebrand Factor-cleaving protease antibodies (“anti-vWF-cp-abs”) from human plasma using human von Willebrand Factor-cleaving protease (“hvWF-cp”) or fragments thereof as affinity ligands. The adsorbents can be used for treating disorders associated with the occurrence of anti-vWF-cp-abs in patients, such as thromboembolic diseases.
Abstract translation: 本发明涉及使用人血管性血友病因子切割蛋白酶（“hvWF-cp”）从人血浆中高度选择性除去抗血管性血友病因子切割蛋白酶抗体（“anti-vWF-cp-abs”）的吸附剂和方法。 或其片段作为亲和配体。 吸附剂可用于治疗与患者中抗vWF-cp-abs的发生相关的疾病，例如血栓栓塞性疾病。
-
8.发明申请PROCEDURE FOR THE GENERATION OF A HIGH PRODUCER CELL LINE FOR THE EXPRESSION OF A RECOMBINANT ANTI-CD34 ANTIBODY 有权用于表达重组抗CD34抗体的高产细胞系的产生方法公开(公告)号：US20090221003A1
公开(公告)日：2009-09-03
申请号：US12389265
申请日：2009-02-19
Applicant: Randolf Kerschbaumer , Petra Boeck-Taferner , Friedrich Scheiflinger
Inventor： Randolf Kerschbaumer , Petra Boeck-Taferner , Friedrich Scheiflinger
IPC: G01N33/566 , C12N5/16 , C07K16/28
CPC classification number: G01N33/6854 , C07K16/2896 , C07K2317/56
Abstract: The present invention relates to cell capture assay for the selection of a high producer cell line expressing anti-CD34 antibodies that recognize the CD34 membrane-protein in the cell membrane. The monoclonal antibody secreted by the hybridoma cell line 9C5/9069 binds to human CD34 and is used to isolate stem cells. The DNA sequences encoding for the antibody heavy and light chain have been identified, isolated from the hybridoma cells and cloned into appropriate expression vectors. After co-transfection of the heavy and light chain genes into HEK293T or in CHO cells either conditioned medium or purified antibody were assessed for binding to CD34 protein located in the cell membrane in different cell capture assays. The binding of the antibody to CD34-positive cells could be shown with these assays for several cell lines.
Abstract translation: 本发明涉及用于选择识别细胞膜中CD34膜蛋白的抗CD34抗体的高生产细胞系的细胞捕获测定。 由杂交瘤细胞系9C5 / 9069分泌的单克隆抗体与人CD34结合并用于分离干细胞。 已经鉴定了编码抗体重链和轻链的DNA序列，从杂交瘤细胞中分离并克隆到合适的表达载体中。 将重链和轻链基因共转染到HEK293T或CHO细胞中后，评估条件培养基或纯化抗体与不同细胞捕获试验中位于细胞膜中的CD34蛋白结合。 抗体与CD34阳性细胞的结合可以用几种细胞系的这些测定法显示出来。
-
公开(公告)号：US20090203110A1
公开(公告)日：2009-08-13
申请号：US12370129
申请日：2009-02-12
Applicant: Bernhard Laemmle , Helena Elisabeth Schaller-Gerritsen , Miha Furlan , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger , Gerhard Antoine , Randolf Kerschbaumer , Luigina Tagliavacca , Klaus Zimmermann
Inventor： Bernhard Laemmle , Helena Elisabeth Schaller-Gerritsen , Miha Furlan , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger , Gerhard Antoine , Randolf Kerschbaumer , Luigina Tagliavacca , Klaus Zimmermann
IPC: C12N9/50
CPC classification number: A61K38/4886 , A61K38/00 , C07K14/755 , C07K16/36 , C12N9/6416 , C12N9/6489 , C12Y304/24087
Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
-
10.发明授权Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV 有权表现出von Willebrand因子（vWF）蛋白酶活性的组合物，其包含具有氨基酸序列AAGGILHLELLV的多肽链公开(公告)号：US07501117B2
公开(公告)日：2009-03-10
申请号：US11166288
申请日：2005-06-23
Applicant: Bernhard Laemmle , Helena Elisabeth Schaller-Gerritsen , Miha Furlan , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger , Gerhard Antoine , Randolf Kerschbaumer , Luigina Tagliavacca , Klaus Zimmermann
Inventor： Bernhard Laemmle , Helena Elisabeth Schaller-Gerritsen , Miha Furlan , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger , Gerhard Antoine , Randolf Kerschbaumer , Luigina Tagliavacca , Klaus Zimmermann
CPC classification number: A61K38/4886 , A61K38/00 , C07K14/755 , C07K16/36 , C12N9/6416 , C12N9/6489 , C12Y304/24087
Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
Abstract translation: 本发明涉及分子量为180kD，170kD，160kD，120kD或110kD的VWF切割实体以及AAGGILHLELLV的N-末端氨基酸序列，vWF切割复合物及其生产方法。
-
-
-
-
-
-
-
-
-
Search Results
80
records
(took 0.021 seconds)
